The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of ...

Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

In silico testing, which uses computer simulations and predictive modeling, is gaining traction due to its ability to provide rapid and cost-effective toxicity assessments. By GLP Type In 2023 ...